Skip to content
Research Article Open access CC BY 4.0

Duchenne Muscular Dystrophy Presenting with Cardiomyopathy and Neurological Decline: A Case Report

Vankodoth Sireesha, Sunkari Nikitha, Kaluvala Ramya, Manne Nikshitha, T. Rama Rao

International Journal of Medical and Pharmaceutical Case Reports · pp. 60–65 · Published 20 Dec 2024

10.9734/ijmpcr/2024/v17i4403

Abstract

Duchenne Muscular Dystrophy (DMD) is a lethal, X-linked neuromuscular disorder caused by the absence of dystrophin protein, which is essential for muscle fiber integrity. It is one of the most severe types of inherited muscular dystrophies affecting approximately 1 in every 3,500 male births worldwide. The estimated prevalence rates of the most common forms of muscular dystrophy are 1 in 5,000 live male births for Duchenne Muscular Dystrophy (DMD). Being the most common and most severe type of muscular dystrophy, Duchenne Muscular Dystrophy (DMD) is caused by mutations in the X-linked dystrophin gene. Loss of dystrophin protein leads to recurrent myofiber damage, chronic inflammation, progressive fibrosis and dysfunction of muscle stem cells. The risk factors associated with DMD include family history, gender, muscle weakness, low BMI, poor lung function and genetic variation. Based on ambulation, the DMD Care Consideration working Group created a classification system for DMD patients. In most cases, there is a delay in motor development, resulting in wheelchair confinement after 3 years of disease and ultimately an early death from respiratory or cardiac issues. It is quite complicated to diagnose DMD due to the limited facilities of genetic testing and its high-cost. The accurate and early diagnosis of DMD plays an important role in effective patient management. In areas with limited facilities, the clinician should conform the DMD not only by anamnesis and clinical features, but also by taking a patient's history, testing for genes and detecting elevated creatine kinase and other transaminases in the lab, progressive motor weakness, myopathies on EMG is still the most significant finding of the illness. Although new treatments continue to strive for a cure for this life-threatening condition, treatment approaches include corticosteroid therapy, intermittent positive pressure breathing have improved function, ambulation, quality of life, and life expectancy. Here, we report a case of a 27 year’s male patient, who has DMD and exhibits notable cardiac, neurological and clinical symptoms. 

Duchenne muscular dystrophy dystrophin ambulation motor development transaminases

References (3)

  1. 1 Vascular therapy for Duchenne muscular dystrophy (DMD) [DOI]
  2. 2 Treating Duchenne Muscular Dystrophy: The Promise of Stem Cells, Artificial Intelligence, and Multi-Omics [DOI]
  3. 3 A child with duchenne muscular dystrophy: A case report of a rare diagnosis among Africans [DOI]

Cited by 2

Overlapping phenotype of GNE myopathy and dystrophinopathy: a rare case with dual variants from India

Tamali Halder, Deepika Joshi, Parimal Das · Journal of Rare Diseases · 2026

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

24

Page views

0

PDF downloads

2

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.